After a diagnosis of long COVID, patients in Colorado shifted from seeking care in hospitals and emergency departments (EDs) ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals' ...

The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ ...

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

The drug, Journavx, or suzetrigine, was approved to treat moderate to severe acute, or short-term, pain in adults. Experts say the drug, which is billed as nonaddictive, could reduce the number ...

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction of a first-in-class non-opioi ...

Vertex Pharmaceuticals claimed in a press release that the medication can be used for many types of moderate-to-severe acute pain and has shown no evidence that it is addictive, like opioids.

The FDA said clinical trials had showed that Jounavx reduced pain after surgery, and called its approval "an important public health milestone in acute pain management". Every year, tens of thousands ...

Our services are intended for corporate subscribers and you warrant ... we have the opportunity to change the paradigm of acute pain management and establish a new standard of care.” Journavx is ...